Cognito Therapeutics completes enrollment in HOPE pivotal trial for Spectris AD with 670 Alzheimer's patients

Cognito Therapeutics/Spectris AD

Cognito Therapeutics announced completion of enrollment in the HOPE pivotal trial, enrolling 670 participants across 70 U.S. clinical sites. The trial is the largest medical device study exclusively focused on Alzheimer's disease and evaluates whether daily home use of Spectris slows cognitive and functional decline; topline data expected in mid-2026.

• 670 patients enrolled in HOPE pivotal trial across 70 U.S. sites, the largest medical device trial exclusively for Alzheimer's.
• Spectris AD uses synchronized 40 Hz light and sound stimulation to enhance gamma brain oscillations.
• FDA Breakthrough Device designation received, enabling expedited review pathway to potential 2027 launch.